Fertility preservation in young women with cancer


Cancer is the second leading cause of death during the reproductive years in women. As long term survival is improving, fertility becomes more important. However, fertility may be influenced by surgery and by gonadotoxic effects of chemotherapy and/or radiotherapy. Therefore, fertility sparing treatments are offered to young women in order to maintain the possibility to conceive after cancer treatment. This is associated with deviation of standard treatment and many different strategies are applied among different centers. In addition, there is a lack of studies investigating the oncological safety and obstetric outcome of these fertility sparing treatments.


What is the oncological and obstetric outcome of fertility sparing treatments in women <40 years?
The purpose of this study is to obtain relevant evidence on the efficacy and safety of fertility sparing cancer treatment in order to better inform clinicians and patients regarding these treatments.

Study design

International multicentre prospective observational trial.
Registration of the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded. The results of the study population are compared to women undergoing standard cancer treatment.

Verwacht aantal patiënten

We aim for at least 500 cases per tumour type and 1 control patient per study patient. This is a minimum that allows us to calculate the oncological prognosis.


Currently, we estimate the study to run until at least 2032.


Prof. dr. Frédéric Amant
UZ Leuven, Department of Gynaecological Oncology
Herestraat 49
3000 Leuven, België
Phone: +32 16 34 42 52, E-mail: Frederic.amant@uzleuven.be


Dr. C.A.R. Lok
Center of Gynecological Oncology Amsterdam, Location Antoni van Leeuwenhoek
Plesmanlaan 121
1066 CX Amsterdam, The Netherlands
Phone: +31 20 512 29 75, E-mail: c.lok@nki.nl

International study in cooperation with ‘The International Network on Cancer, Infertility and Pregnancy’ (INCIP). Substudy of the ‘Cancer in Pregnancy’ study. Sponsor of the trial are the University Hospitals of Leuven, Belgium. Worldwide collaboration is necessary to include sufficient number of patients.

An updated list of participating sites per country can be found on: https://clinicaltrials.gov NTC 02878434

No funding.
A request for KWF funding will follow.